Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

Phase 3

Completed

• Conditions: Psychotic Disorder; Body Weight Change; Schizophrenia; Schizoaffective Disorder

• Registration Number: NCT00095524
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Study First Submitted: 2004-11-05
• Study First Submitted QC: 2004-11-05
• Study First Posted: 2004-11-08
• Primary Completion: 2006-08
• Study Completion: 2006-08
• Status Verified: 2008-05
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Adult patients diagnosed with schizophrenia or schizoaffective disorder who are currently taking olanzapine.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Comparison of weight change from baseline to Week 16 in patients with schizophrenia or schizoaffective disorder treated with aripiprazole or olanzapine

Secondary Outcome Measures

Name	Time	Method
Assessment of metabolic laboratory measures

Trial Locations

Locations (1)

Local Institution; 🇬🇧 Birmingham, West Midlands, United Kingdom